KTTA
NASDAQ · Biotechnology
Pasithea Therapeutics Corp
$0.52
-0.01 (-2.27%)
Open$0.55
Previous Close$0.53
Day High$0.55
Day Low$0.50
52W High$2.06
52W Low$0.28
Volume—
Avg Volume2.89M
Market Cap19.34M
P/E Ratio—
EPS$-1.48
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+5,077.9% upside
Current
$0.52
$0.52
Target
$26.92
$26.92
$19.73
$26.92 avg
$29.00
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 437.7K | 3.90M | 3.72M |
| Net Income | -434,822,155 | 467.4K | 601.6K |
| Profit Margin | -14,394.0% | 12.0% | 16.2% |
| EBITDA | -434,805,448 | 1.16M | 1.10M |
| Free Cash Flow | — | 801.3K | 617.9K |
| Rev Growth | — | +18.2% | +4.0% |
| Debt/Equity | — | 0.89 | 0.81 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |